Cyrus Biotechnology Inc. has reported data on its engineered IdeS (IgG-degrading enzyme of S. pyogenes) protease for IgG-driven autoimmune disease, showing potent activity on repeat doses in a rabbit redosing model while eliciting no anti-drug antibodies.
In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid manufactured anti-CD19/CD20 CAR T-cell therapy being developed for the treatment of B-cell malignancies.
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for degradation. “Insulin was discovered 100 years ago, and the insulin receptor was discovered 50 years ago,” Heiko Lickert told BioWorld. “Now we have a new insulin receptor, which degrades insulin.” Lickert is the senior author of the paper reporting the new insights into how inceptor works, which were published online in Nature Metabolism.
Relation Therapeutics Ltd. has delivered the first commercial validation of its combined wet lab/in silico platform for homing in on disease-related genes in the thick of the genome, signing two collaboration agreements with GSK plc, with a potential value of $200 million per target.
Mirati Therapeutics Inc. has divulged GTPase KRAS (G12S mutant) and/or GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.
Researchers at Stichting AMC Foundation and Vrije Universiteit van Amsterdam have identified [18F]-labeled pyrazolidine-3,5-dione compounds targeting P2Y purinoceptor 12 (P2RY12; P2Y12) acting as PET and SPECT imaging agents. They are reported to be useful for the diagnosis of multiple sclerosis, Alzheimer’s disease and Parkinson’s disease.
Scientists at Daegu-Gyeongbuk Medical Innovation Foundation and Korea Research Institute of Chemical Technology have synthesized phenaleno-isoquinolinium-based compounds reported to be useful for the treatment of cancer.
RSS
